Document is current

Article History

Received: 24 July 2024

Accepted: 2 September 2024

First Online: 17 September 2024

Declarations

:

: This study was approved by the Hospital Universitari de Bellvitge Research Ethics Committee. The patients signed informed consent forms, and the data were collected anonymously.

: In the last three years, LB has received funding for travel and congress expenses and honoraria for lectures from Biogen, Bristol Myers Squibb, Merck, Novartis and Roche. EM has received funding for travel and congress expenses and honoraria for lectures from Biogen, Bristol Myers Squibb, Merck and Janssen. LRP has received funding for travel and congress expenses and honoraria for lectures from Biogen, Bristol Myers Squibb, Novartis, Merck, Roche and Teva. IL has received funding for travel and congress expenses from Biogen, Merck, Novartis and Roche. AMV has received honoraria or funding for travel and congress expenses from Teva, Lilly, Lundbeck, Organon, UCB, Bial, Chiesi, Allergan, Kern Pharma, Pfizer, Biogen, Novartis, Merck, Janssen, Sanofi and/or Bristol Myers Squibb. PAP has received funding for travel and congress expenses from Novartis, Roche and Sanofi. AMY has received support for congress attendance from Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche and Sandoz. SMY has received support for congress attendance from Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche and Sandoz. The institution where the authors work (Hospital Universitari de Bellvitge/ Institut d’Investigació Biomèdica de Bellvitge) has received in the last three years and dedicated exclusively to support the research of the Unit, fees for advisory council, collaborations, donations and advice from Almirall, Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Horizon/Amgen, Janssen, Kern Pharma, Lilly, Merck, Neuraxpharm, Novartis, Roche, Sandoz and Sanofi.